ImmVirX develops receptor-targeted oncolytic viruses for cancer treatment, focusing on prevalent cancer types with limited treatment options.

ImmVirX

ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect.  The company is developing a bio-selected RNA virus to induce tumour inflammation and achieve immune cell infiltration via the RIG-I pathway. The targets for this approach are Ovarian, Head & Neck and those indications which present with liver metastases such as Colorectal, Hepatocellular carcinoma and Pancreatic cancer. The approach includes combination therapy with Immune Checkpoint Inhibitors and CAR-T agents using bio-selected RNA virus.
The company founders, Malcolm McColl and Prof. Darren Shafren, were Managing Director and CSO of Viralytics, an ASX listed oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million.  The ImmVirX team includes key management and researchers from Viralytics and is based at the former Viralytics laboratory facilities in Newcastle Australia.

Great update on our clinical program by CEO Malcolm McColl and CSO Darren Shafren on Oncology for the Inquisitive Mind Podcast. Thank you to the team for inviting us on to share our recent progress.

ImmVirX has presented an update showing promising signals in its Phase 1a/b study targeting solid cancers at the MOGA Annual Meeting.   IVX037 has been well tolerated, with signs of monotherapy activity, in particular in late-stage colorectal cancer patients: https://buff.ly/3Mac4Mw

ImmVirX is pleased to have CSO Darren Shafren and Medical Director Oksana Zdanska attending the 2024 Medical Oncology Group of Australia (MOGA) Annual Scientific Meeting this week. 

An update from the phase 1a monotherapy trial of our lead candidate, IVX037 will be provided in a Poster presentation from Dr Jia (Jenny) Liu on 15th August. A Phase 1b featuring IVX037 in combination with Innovent's checkpoint inhibitor TYVYT will commence in the coming months.

ImmVirX is pleased to advise that Co-Founder and CEO Dr Malcolm McColl's presentation at The Bell Potter Securities Healthcare Conference 2023 is now available.

Click here to view the presentation: https://lnkd.in/gpQxeAH7

We are pleased to announce the appointment of Dr Oksana Zdanska as Medical Director, commencing today: https://buff.ly/49y35hH

Dr. Zdanska is a highly regarded clinical leader with extensive experience in clinical trials, including drug development of novel treatments. She has know-how and familiarity with cutting edge technologies including the use of oncolytic immunotherapies in clinical settings.

We are pleased to share a replay of CEO & Acting Chairman Dr Malcolm McColl's presentation at the NWR Virtual Healthcare Conference.

Shareholders and other interested parties can view the presentation at: https://buff.ly/3PLzXfE

Metric
Company Name	ImmVirX
Symbol
MSH ID	COM:IMMVIRX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	AU
Stage
Employee Count	24
Website	immvirx.com
LinkedIn	immvirx
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

IMMV

COM:IMMVIRX

ImmVirX

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue